HE 317
Latest Information Update: 04 Jul 2003
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Developer Hollis-Eden Pharmaceuticals
- Class Antivirals
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 04 Jul 2003 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
- 20 Apr 1999 Preclinical development for HIV infections treatment in USA (Unknown route)